Table 3 Treatment and outcome of patients with brain metastases.
Case | Age | Sex | HER2 status | Treatment regimen | Treatment line brain metastases were diagnosed | Treatment of brain metastases | Survival after diagnosis of brain metastases (months) | |||
|---|---|---|---|---|---|---|---|---|---|---|
1st line | 2nd line | 3rd line | 4th line | |||||||
1 | 75 | M | + | XP + Tmab | PTX | 0 | SRT | 12.4 | ||
2 | 63 | M | − | SP | PTX | 2 | BSC | 0.8 | ||
3 | 74 | M | − | XP | PTX + study drug | 2 | BSC | 0.6 | ||
4 | 70 | M | + | XP + Tmab | PTX + RAM | NIVO | CPT-11 | 3 | SRT | 4.9 |
5 | 41 | F | − | XELOX | Nab-PTX + RAM | NIVO | CPT-11 | 3 | Surgery | 16.9 |
6 | 71 | F | − | XELOX | Nab-PTX | 2 | WBRT | 1.2 | ||
7 | 75 | M | − | XELOX | Nab-PTX + RAM | FTD/TPI | NIVO | 1 | Surgery | 13.5 |
8 | 68 | M | − | SOX | 1 | BSC | 1.0 | |||
9 | 76 | M | − | SOX | 1 | Surgery | 0.4 | |||
10 | 76 | M | − | XELOX | PTX + RAM | NIVO | 3 | SRT | 2.8 | |
11 | 64 | M | + | XELOX + Tmab | 1 | SRT | 11.4 | |||
12 | 56 | F | − | SOX | 0 | Surgery | 2.1 | |||
13 | 71 | F | + | XELOX + Tmab | Nab-PTX + RAM | NIVO | T-Dxd | 2 | SRT | 5.6 |
14 | 62 | M | − | XELOX | PTX + RAM | 2 | WBRT | 0.5 | ||
15 | 78 | M | − | S1 | 0 | SRT | 3.5 | |||
16 | 73 | M | + | SOX + Tmab | PTX | T-Dxd | 1 | SRT | 2.1 | |
